港股科技50ETF(513980) 连续4日获得场外资金净申购！增量资金流入有望继续支撑港股牛市

Core Viewpoint - The Hong Kong stock market opened with collective gains, particularly in the biopharmaceutical sector, driven by expectations of a potential interest rate cut by the Federal Reserve in December 2025, which may alleviate liquidity constraints affecting market performance [1] Group 1: Market Performance - As of 11:30 AM, the Hong Kong Technology 50 ETF (513980) rose by 0.93%, marking its fourth consecutive trading day of net subscriptions from external funds [1] - Notable individual stocks included Health Road, which increased by over 7%, Meituan-W rising over 5%, and both Sangfor Technologies and Kangfang Biotech gaining over 4% [1] Group 2: Federal Reserve Influence - A Federal Reserve board member advocated for a rate cut in December, leading to heightened market expectations for this move, which could ease previous liquidity pressures on the Hong Kong stock market [1] Group 3: Future Market Outlook - According to Guotai Junan Strategy, the combination of incremental capital inflows and the gathering of quality assets suggests that the bullish trend in the Hong Kong stock market is likely to continue [1] - If short-term factors that have been suppressing the market are resolved, the mid-term outlook remains positive with clear incremental capital and a concentration of scarce quality assets in China [1] Group 4: Investment Opportunities - The Hong Kong Technology 50 ETF (513980) closely tracks the CSI Hong Kong Stock Connect Technology Index, which includes major tech leaders like Alibaba [1] - Investors are encouraged to consider the Hong Kong Technology 50 ETF (513980) and its associated funds (Class A: 016495; Class C: 016496) to capitalize on quality assets in the Hong Kong market [1]